New treatment for metastatic nasopharyngeal cancer before chemotherapy
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new treatment for people with advanced nasopharyngeal cancer that has spread (stage IVb) and who have not yet had chemotherapy. It aims to see if the experimental treatment is safe and effective as a first option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a diagnosis of stage IVb nasopharyngeal carcinoma that has spread to other parts of the body.
- You must not have received platinum-based chemotherapy as your first treatment for the metastatic cancer.
- You must have at least one tumor that can be measured by scans.
- You must not have had immunotherapy or anti-angiogenic therapy before.
- You must be willing to use contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
Hear when a new Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.